sorafenib has been researched along with plerixafor in 5 studies
| Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (plerixafor) | Trials (plerixafor) | Recent Studies (post-2010) (plerixafor) |
|---|---|---|---|---|---|
| 6,520 | 730 | 5,251 | 1,312 | 113 | 930 |
| Protein | Taxonomy | sorafenib (IC50) | plerixafor (IC50) |
|---|---|---|---|
| C-X-C chemokine receptor type 4 | Rattus norvegicus (Norway rat) | 0.108 | |
| C-C chemokine receptor type 2 | Homo sapiens (human) | 0.0001 | |
| C-X-C chemokine receptor type 4 | Homo sapiens (human) | 0.3717 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Fan, L; Han, TT; Li, JY; Xu, W | 1 |
| Chen, Y; Chern, GG; Chiang, T; Gao, DY; Lin, TT; Liu, CH; Liu, JY | 1 |
| Chen, J; Jia, H; Lu, L; Lu, M; Pei, Y; Qin, L; Zhu, W | 1 |
| Andreeff, M; Borthakur, G; Chen, HC; Cortes, JE; Daver, N; Huang, X; Kadia, T; Kantarjian, H; Kelly, MA; Konopleva, M; McQueen, T; Patel, KP; Ravandi, F; Wang, RY; Zeng, Z | 1 |
2 review(s) available for sorafenib and plerixafor
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Role of chemokines and their receptors in chronic lymphocytic leukemia: function in microenvironment and targeted therapy.
Topics: Aminopyridines; Antineoplastic Agents; Benzylamines; Chemokine CXCL12; Clinical Trials as Topic; Cyclams; Dasatinib; Heterocyclic Compounds; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Molecular Targeted Therapy; Morpholines; Niacinamide; Oxazines; Phenylurea Compounds; Protein Kinase Inhibitors; Purines; Pyridines; Pyrimidines; Quinazolinones; Receptors, CXCR4; Sorafenib; Thalidomide; Thiazoles; Tumor Microenvironment | 2014 |
1 trial(s) available for sorafenib and plerixafor
| Article | Year |
|---|---|
Phase 1 study of combinatorial sorafenib, G-CSF, and plerixafor treatment in relapsed/refractory, FLT3-ITD-mutated acute myelogenous leukemia patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzylamines; Cyclams; Disease-Free Survival; Female; fms-Like Tyrosine Kinase 3; Granulocyte Colony-Stimulating Factor; Heterocyclic Compounds; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Sorafenib; Survival Rate | 2020 |
2 other study(ies) available for sorafenib and plerixafor
| Article | Year |
|---|---|
Delivery of siRNA Using CXCR4-targeted Nanoparticles Modulates Tumor Microenvironment and Achieves a Potent Antitumor Response in Liver Cancer.
Topics: Angiogenesis Inhibitors; Animals; Benzylamines; Carcinoma, Hepatocellular; Cell Line, Tumor; Chemokine CXCL12; Cyclams; Disease Progression; Genetic Therapy; Heterocyclic Compounds; Humans; Liver Neoplasms; Male; Mice; Mice, Inbred C3H; Nanoparticles; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Receptors, CXCR4; RNA, Small Interfering; Signal Transduction; Sorafenib; Tumor Microenvironment; Vascular Endothelial Growth Factor A | 2015 |
Down-regulation of SDF1-α expression in tumor microenvironment is associated with aspirin-mediated suppression of the pro-metastasis effect of sorafenib in hepatocellular carcinoma.
Topics: Animals; Aspirin; Benzylamines; Carcinoma, Hepatocellular; Cell Proliferation; Chemokine CXCL12; Cyclams; Down-Regulation; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Heterocyclic Compounds; Humans; Liver Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Metastasis; Neoplasm Transplantation; Niacinamide; Phenylurea Compounds; Receptors, CXCR4; Sorafenib; Tumor Microenvironment | 2015 |